Please assess the completion status of the following clinical trial:

Trial Title: C-Cog in Early Course Schizophrenia Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults~2. Diagnosis of schizophrenia~3. Current Hospitalization or outpatient relapse~4. Fewer than four previous admissions~5. Willing to accept long-acting injectable treatment and participate in rehabilitation~Exclusion Criteria:~1. Primary diagnosis other than schizophrenia~2. Prior Long Acting Injectable treatment~3. Current Suicide Risk~4. Hypersensitivity to Aripiprazole~5. Pregnancy~6. Positive illicit drug screen other than cannabis (rescreening allowed in 4 weeks for drug positive cases)~7. Unable to give personal informed consent~8. History of treatment resistance as evidenced by clozapine treatment~9. Unable to stop treatment with medications that are strong Cytochrome (CYP) 2D6 or CYP 3A4 inhibitors and or strong CYP3A4 inducers (2.3, 7.1) for at 14 days prior to initiation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aripiprazole and Computerized Cognitive and Functional Skills Training Group (Type: EXPERIMENTAL): Participants in this arm will receive long-acting injectable aripiprazole every 2 months formulation for 12 consecutive months. Participants in this arm will also receive Computerized cognitive and functional skills training during the first 12 weeks of study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).